Basilea launching antifungal CRESEMBA® (isavuconazole) in Germany

Basilea Pharmaceutica AG / Basilea launching antifungal CRESEMBA® (isavuconazole) in Germany . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Basel, Switzerland, March 04, 2016 - Basilea Pharmaceutica Ltd. (SIX: BSLN) hosts a symposium to support the launch of the new azole antifungal CRESEMBA^® (isavuconazole) in Germany. The symposium will be held on March 5 and 6, 2016 in Berlin. The symposium is co-chaired by Prof. Oliver A. Cornely, Department of Internal Medicine I, University of Cologne, Germany; and Prof. Andrew J. Ullmann, Julius-Maximilians-University, Department of Internal Medicine II, Infectious Diseases, Würzburg, Germany. The focus of the symposium will be on current challenges and recent developments in the management of invasive mold infections.

David Veitch, Basilea's Chief Commercial Officer, commented: "We are excited to be launching CRESEMBA in Germany. The symposium provides an opportunity for clinicians to discuss important clinical data and share their experiences in relation to the treatment of potentially life-threatening invasive mold infections. CRESEMBA addresses an important medical need of immunocompromised patients. We are focused on rolling out CRESEMBA in our core European markets this year."

CRESEMBA^® (isavuconazole) was approved by the European Commission in October 2015 for the treatment of adults with invasive aspergillosis and the treatment of adults with mucormycosis for whom amphotericin B is inappropriate. Invasive aspergillosis and mucormycosis are life-threatening fungal infections that often affect immunocompromised patients, such as patients with cancer and after transplantation. Invasive aspergillosis is often fatal. Mucormycosis (also known as zygomycosis) is a rapidly progressive and life-threatening invasive fungal infection, often affecting the nose and sinuses with high mortality.

Prof. Andrew J. Ullmann stated: "Clinicians have with isavuconazole a new antifungal agent with a broad spectrum activity against invasive fungal diseases and an improved safety profile. The combination of these features demonstrates clearly that isavuconazole is an improvement for the care of our patients with severe invasive fungal diseases."

About CRESEMBA® (isavuconazole)

Isavuconazole is an intravenous and oral azole antifungal and the active agent of the prodrug isavuconazonium sulfate. Isavuconazole was co-developed with Astellas Pharma Inc. under an agreement granting Astellas a license to commercialize isavuconazole in the U.S. Basilea holds full isavuconazole rights in markets outside the United States. Isavuconazole is marketed under the trade name CRESEMBA^®. The drug was approved in March 2015 by the U.S. FDA for the use for patients 18 years of age and older in the treatment of invasive aspergillosis and invasive mucormycosis. The European Commission granted marketing authorization in October 2015 to isavuconazole for the treatment of adult patients with invasive aspergillosis and for the treatment of adult patients with mucormycosis for whom amphotericin B is inappropriate. The European marketing authorization is valid in all 28 European Union (EU) member states, as well as in Iceland, Liechtenstein and Norway. Isavuconazole has orphan drug designation for the treatment of invasive aspergillosis and mucormycosis in Europe and the U.S.